We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
+13.64%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.46B
AUM Growth
+$126M
Cap. Flow
-$103M
Cap. Flow %
-4.19%
Top 10 Hldgs %
40.31%
Holding
211
New
10
Increased
47
Reduced
69
Closed
17

Top Buys

Rank Stock Value
1
PFE icon
Pfizer
PFE
+$23.4M
2
MRK icon
Merck
MRK
+$20M
3
WELL icon
Welltower
WELL
+$14.4M
4
CI icon
Cigna
CI
+$9.62M
5
LLY icon
Eli Lilly
LLY
+$9.59M

Top Sells

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$25.4M
2
JNJ icon
Johnson & Johnson
JNJ
+$18M
3
ALXN
Alexion Pharmaceuticals
ALXN
+$15M
4
ABBV icon
AbbVie
ABBV
+$14.1M
5
VTRS icon
Viatris
VTRS
+$13.4M

Sector Composition

Rank Sector Weight
1 Healthcare 94.43%
2 Real Estate 2.93%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
EW icon
51
Edwards Lifesciences
EW
$50B
$10.9M 0.44%
170,394
– –
ZBH icon
52
Zimmer Biomet
ZBH
$18.4B
$10.2M 0.41%
82,044
-9,836
-11% -$1.12M
JAZZ icon
53
Jazz Pharmaceuticals
JAZZ
$16.2B
$9.64M 0.39%
67,471
-47,716
-41% -$6.22M
KYNB
54
Kyntra Bio
KYNB
$27.5M
$9.55M 0.39%
7,030
-1,481
-17% -$2.01M
NKTR icon
55
Nektar Therapeutics
NKTR
$2.41B
$9.53M 0.39%
18,912
+12,620
+201% +$7.48M
HUM icon
56
Humana
HUM
$44B
$9.49M 0.39%
35,682
-32,805
-48% -$9.45M
BPMC
57
DELISTED
Blueprint Medicines
BPMC
$9.26M 0.38%
115,720
-9,487
-8% -$701K
GSK icon
58
GSK
GSK
$104B
$9.14M 0.37%
174,960
– –
SBRA icon
59
Sabra Healthcare REIT
SBRA
$5.38B
$9.08M 0.37%
466,247
-76,615
-14% -$1.45M
IONS icon
60
Ionis Pharmaceuticals
IONS
$8.81B
$8.91M 0.36%
109,720
+26,882
+32% +$1.73M
ARRY
61
DELISTED
Array Biopharma Inc
ARRY
$8.88M 0.36%
364,166
– –
XLRN
62
DELISTED
Acceleron Pharma
XLRN
$8.77M 0.36%
188,388
+17,622
+10% +$774K
MCK icon
63
McKesson
MCK
$101B
$8.28M 0.34%
70,720
-8,000
-10% -$987K
MDCO
64
DELISTED
Medicines Co
MDCO
$8.2M 0.33%
293,392
-135,600
-32% -$3.2M
XBI icon
65
State Street SPDR S&P Biotech ETF
XBI
$10.3B
$8.06M 0.33%
89,022
-55,402
-38% -$4.71M
ALGN icon
66
Align Technology
ALGN
$12.4B
$8.04M 0.33%
28,278
-1,582
-5% -$378K
SNY icon
67
Sanofi
SNY
$103B
$7.97M 0.32%
179,900
– –
XRAY icon
68
Dentsply Sirona
XRAY
$2.75B
$7.76M 0.32%
156,521
+30,896
+25% +$1.36M
SNN icon
69
Smith & Nephew
SNN
$13.6B
$7.44M 0.3%
185,478
– –
ESPR
70
DELISTED
Esperion Therapeutics
ESPR
$7.41M 0.3%
184,607
+42,318
+30% +$1.9M
STRO icon
71
Sutro Biopharma
STRO
$411M
$7.3M 0.3%
64,127
+41,137
+179% +$4.28M
ALKS icon
72
Alkermes
ALKS
$8.39B
$7.23M 0.29%
198,048
+46,765
+31% +$1.54M
ASND icon
73
Ascendis Pharma A/S
ASND
$16.5B
$7.22M 0.29%
61,360
+18,961
+45% +$1.66M
RMD icon
74
ResMed
RMD
$30.3B
$7.17M 0.29%
68,974
+10,344
+18% +$1.07M
PVLA
75
Palvella Therapeutics
PVLA
$2.15B
$6.99M 0.28%
26,092
– –
1 2
3
4 5

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q1 2019 Portfolio in Review

As of Q1 2019, Tekla Capital Management held 211 positions worth $2.46B, up 5.4% from $2.34B the previous quarter. Its ten largest holdings account for 40% of the portfolio.

Tekla Capital Management withdrew a net $103M in Q1 2019, closing 17 positions and reducing 69 holdings. Its most notable exit was Shire pic, an estimated $6.3M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, up from 94% a quarter earlier, followed by Real Estate.

Against the trend, Tekla Capital Management opened a new position in Bio-Techne worth $4.31M.

  • Tekla Capital Management's largest Q1 2019 buy was Bio-Techne: 86,804 shares worth $4.31M.
  • Tekla Capital Management added most to Pfizer in Q1 2019, an estimated $23.4M increase.
  • Tekla Capital Management's biggest Q1 2019 reduction was Biogen, cutting an estimated $25.4M.
  • Tekla Capital Management fully exited Shire pic in Q1 2019, selling an estimated $6.3M.
  • Tekla Capital Management's ten largest holdings make up 40% of its $2.46B portfolio in Q1 2019.
  • Tekla Capital Management opened 10 new positions and closed 17 in Q1 2019.
  • Tekla Capital Management's portfolio value rose 5.4% quarter-over-quarter to $2.46B.

Based on Tekla Capital Management's 13F filing for Q1 2019, filed 14 May 2019.